Mr. Rene Goehrum reports

BIOSYENT ANNOUNCES RENEWAL OF NORMAL COURSE ISSUER BID

The TSX Venture Exchange has accepted BioSyent Inc.'s notice of intention to make a normal course issuer bid. Pursuant to the NCIB, BioSyent may purchase up to 800,000 of its common shares over a 12-month period, representing approximately 7.1 per cent of the shares outstanding as of Dec. 15, 2025.

The NCIB will commence on Dec. 19, 2025, and terminate on Dec. 18, 2026, or such earlier date on which purchases under the NCIB have been completed. Purchases of shares under the NCIB will be made through the facilities of the TSX-V or alternative Canadian trading systems at the market price of the shares at the time of acquisition. The number of shares the company is permitted to purchase during any 30-day period is limited to 225,245 shares, representing 2 per cent of the total outstanding shares. It is the company's intention to cancel the majority of the shares repurchased with a limited number of shares to be held in trust for future issuance under the company's RSU plan. All shares repurchased under the NCIB will be financed from the company's cash reserves.

BioSyent has entered into an automatic share purchase plan with a broker, Raymond James Ltd., in connection with the NCIB to allow for the purchase of Shares during certain predetermined blackout periods. Outside of these predetermined blackout periods, shares will be purchased at the discretion of senior management of BioSyent.

BioSyent believes that the shares may from time to time trade in a price range that does not adequately reflect the value of the shares in relation to its activities and future prospects. As a result, BioSyent believes that the purchase of shares, from time to time, would be an appropriate use of corporate funds in light of potential benefits to remaining shareholders.

BioSyent has repurchased and cancelled a total of 3,112,525 shares under NCIBs between Dec. 10, 2018, and Dec. 15, 2025, at an average price of $7.14 per share. During the most recent NCIB, between Dec. 19, 2024, and Dec. 15, 2025, BioSyent has repurchased and cancelled a total of 124,500 shares at an average price of $11.21 per share.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other health care products that have been successfully developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals who treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this news release, the company has 11,262,282 common shares outstanding.

We seek Safe Harbor.